joining thank us. and Thank you, afternoon Matt. you all Good for
markets as deal in results even continue a unpredictable make our good relatively progress the We continue environment. to to with business healthcare
for while on important drivers moving During revenue quarter, initiatives gross believe we be increased both strategic value company. forward will the that we margin, and the third
advancing data reimbursement with These approach supporting to peripheral into include markets development program to clinical enable best-in-class us portfolio, product and our existing our and expanding codes. coronary platform image-guided enter generating large our product new technology
over what contributor quarter summer the the procedural during grew quarter Lightbox our sales typically supported important X third year. an growth volume new X% seasonally this revenue We quarter, quarter third in launch of a the for were over to the months. slower second console Capital is imaging our earlier by
this device patient of PAD. Our lesions, continues physicians below-the-knee SV with outcomes from well small population, to most and the very thrilled in ischemia, clinical are atherectomy and of in Pantheris CLI, vessel anatomy market. primarily limb whom many perform severe SV the used challenging to we is the form suffer Pantheris achieving are treat or critical
vascular for The real-time disease by imaging vessels. within of when arterial to and precisely working are damage the structures, technology to physicians avoiding the provided our to importance proprietary paramount narrow these precise diameter X control millimeter critical while target X
make We setting. for a post-market to of progress to treatment in in the our continue of lesions real-world the Pantheris SV study IMAGE-BTK clinical below-the-knee evaluate designed enrollment
early clinical intervals have Germany up in the patients to one the enrolling post and study two with now of to to We enroll in evaluated at in study We expect centers sites completion the and year XX clinical XXXX. two up anticipate procedure. patients U.S. enrollment in in
adverse blockage update XX index from findings zero conference Demonstrating and the population investigator the early principal events outstanding. reduction procedure. from results complications An clinical following with on percent days in image-guided within in effectiveness of XX% Most the interim the the study. continue patients IMAGE-BTK was study the at or August the limb the and physicians have by or approach, our safety achieved stenosis treatment of be suffer this in enrolled in to IMAGE-BTK ischemia AMP patient in presented critical clinical challenging
standard patency one-year a Interim from are life-changing XX% exciting, simply months. to patency of target patients patients of re-stenosis vessel encouraging at otherwise with are procedures. having showing since in is significant types patients assessing data XX ultrasound outcomes for and study freedom of reaching being would duplex These many endpoint XX% for the after of equally results gold often these This with the risk be of the is treated, whom considered quite patients of amputation. particularly
to X another accounts driver. of new advanced incredible value our of both more imaging sites. in and the over and portable Lightbox Turning in XXX we been initiated has key in Lightbox platform. next-generation existing highly commercial XX this than used launch cases and continue to demonstrate April, console X now We the and
pronounced At enhanced the high-definition more easier system. with the physicians with the to Lightbox physicians the XX on that have be than this this imaging and of various image used excellent, feedback many new is are continues console details plaque more point, and by types reporting structures this X of interpretation that and provided new arterial
and opens our launched new opportunities our of by capital expansion identification five the equipment. of the and third piece console to allowing clinical upgrade a user Lightbox or placement capital prior and sales evaluation new to initiate or of of new sales exciting quarter the X opportunity. quarter efficient our for of of leverage our sales new catheters for base of portability The top accounts eight in accounts technology on utilization second new we a to for this a rep the company in We specialist of continue contracting launched
In across peripheral a new advanced the next-generation and for filing we CTO and interpretation image for Tigereye total chronic our for front, system response expansion catheter, ST three-marker integrated in torque of advanced progress an platform. to facilitate a and use XXX(k) regulatory new catheter catheter blockages tip has the pushability our outer the or incorporates This design devices. new CTO-crossing arteries. On penetrating our occlusion for on an with shaft system a caps, consistent submission portfolio adds challenging image-guided for announced of spinning to make we product filing peripheral and July, continue two development
catheters market By the adding advanced image-guided Tigereye the for our device capabilities advanced addressable ST utility of to to new CTO in disease. expand expected the is treatment and platform, the
XXX(k) once and commercial new has submission full we FDA, limited clearance to FDA first the clinical receive around half with of receive past proceeding we of introductions, anticipated a will a clearance XXXX. process catheter the hope to in through progressing with FDA been Consistent in select Our initiate number sites launch prior year-end. launch we to the clearance,
quickly in treatment popliteal the device are arteries, be of above procedures will PAD and are our treat LV, the Pantheris device new atherectomy used the development behind to SFA larger knee, and lesions where vessels. today. also We of the This moving of for the on performed image-guided majority primarily
successful to plaque catheter the Pantheris system and our to Pantheris LV streamline apposition design capabilities balloon modified and at procedural rotational this need Pantheris a anatomy. proprietary expand of speeds design procedure to further to efficiency. highly guidewire the without It leverages a designed elements for is LV in SV and plaque. implements for our operate plaque higher a challenging engage enhances improve management significantly management also utilizes
launch midyear with the of new XXX(k) the application would to up in FDA device year. of half file commercial this which anticipated near year-end, device XXXX, efficient this highly a second expect clearance by set new for We
year. in half of first the of half the year in second our the represent image-guided With our Tigereye in a of launch devices single atherectomy would launch year, device highly LV with of the two commercial for ST anticipated year Pantheris the XXXX anticipated a launch Avinger CTO-crossing the banner of and anticipated device the
in our new with Lightbox technology and leadership In combination console, provide will X catheters believe space we these clinically opportunities new our growth a new important assert for our imaging company.
about to making in first progress we very coronary the to technology look application. markets, our we we development of expand are are product As new the excited our
our in invasive arteries. Coronary artery with the believe CAD, less fully the revolutionize or the system proprietary percutaneous CTOs integrated existing and We to coronary with codes opportunity crossing reimbursement addressable of this in massive technology image-guided market represents provides the market first only for place. disease, that a
procedures across By we what platform, arteries experience safe, is providing we've leveraging can with in peripheral by a steep believe the we require redefine made a complex, our PCI expensive devices. to today multiple a Current highly of a procedure. crossing and use complex, solution and technique and demanding patient-oriented CTO reliable, technological curve and learning category specialized the the uncertain are our advances
extended health require time exposure radiation results under procedures fluoroscopy, for risks team in and These creating medical high X-ray burden, which contrast the media patients. both and
artery of treatment up procedures, coronary In of addition, to annually with to that or CABG in related coronary surgeries the estimates XX% are XXX,XXX more bypass invasive of than estimated these grafting, the it U.S. highly CTOs. is performed
reduce upon and which diagnostic system, percutaneous during with clearance as exciting would An contrast image-guided in more device reimbursement the the for coronary a This procedure physicians and for X-ray to market image-guided access an reimbursement as approach target radiation attractive provides procedure. would the immediately capabilities burden accessible make FDA highly exposure imaging existing diagnostic arteries. CTO-crossing OCT coronary well therapeutic our
devices, provides for reimbursement a the catheter proposition. scenario, an that designed with an compelling crossing image-guided with value fewer for believe efficiency combined We need economic support for the attractive opportunity
combine on and real-time CTOs. focused approach control and designs an efficiently that with facilitate physicians coronary to catheter and profile steerability are cross to efforts safely low OCT development CTO allow guidance coronary Our antegrade precise
to help measurement physicians will is which balloons properly Similar critical our optimal placement, coronary stents incorporate capability to size outcomes. devices our or peripheral prior catheters, precise to for a
coronary crossing catheter system innovations capabilities Our devices Lightbox our CTO in X new imaging and technologies. the advanced recent will of our leverage
and with highly catheter progress We design continue the good of and make to our cardiologists. engagement models development experienced through evaluation in candidates interventional internal on
represented device coronary allow plan to regulatory program As and safety near our initiation R&D in our study and in clinical device investigational vast goal with advance of the XXXX, a on markets, IDE, the completion with the of coronary efforts light of evaluate our XXXX or potential prioritizing an peripheral filing on we development of in of to the in programs for the filing. FDA a efficacy exemption, the by
year to end three business. are the on execution peripheral and focusing to drive of areas growth in XXXX, this push we As our for we prepare of strategic
base case utilization commercial will console. new for through launch second, in we increasing core platform. create volume and Lightbox XXXX, through for And sales our process third, new the our X our in team; our of and driving imaging user which drivers First, the advancing the account product our believe in geographic of deployment through catheter efforts portfolio approval our devices areas broaden and appeal activity usage direct expanding two new preparation of our regulatory peripheral new opportunities
challenging As R&D CTO and and procedures PCI time-consuming XXXX our are provides focus will this CTO to to advance the effective safe, image-guided future, program. redefine with our our performed We primary in how efficient coronary procedure. platform we believe the to look be approach opportunity more to a
about We imaging the place. our and proposition excited are OCT in provide reimbursement market approach that for to both this large CTO-crossing codes would underserved technology-enabled diagnostic economic value with and already
are we the care is innovative about so, vascular physicians providing mission with tool an advance new for treated. by excited changing of to radically most possible support And their our patients. best providing them the doing Yet disease in way
At Principal I'd the Financial point, through and to Officer, and Accounting will call the I our turn to Subainati, like for this then us Nabeel Q&A. over Nabeel? financial take return results, to
